Loading
A phase 1/2 trial of MBS303 in non-Hodgkin lymphoma, run by Beijing Mabworks Biotech Co., Ltd., now recruiting.
A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL is a phase 1/2 interventional study registered as NCT05806099 by Beijing Mabworks Biotech Co., Ltd., with 132 participants planned, started 2023-06-28 and due to reach its primary completion in 2025-11. Interventions recorded: MBS303.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Beijing Mabworks Biotech and the tag pipeline.
Shares Beijing Mabworks Biotech and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/